• Type:
  • Category:

Carl Zeiss Meditec AG Financial Results H1 2021/22 | Performance Insights with CEO and CFO

Share

Carl Zeiss Meditec AG H1 2021/22: Key Takeaways

Carl Zeiss Meditec AG Demonstrates Growth Amidst Global Challenges

In an insightful video presentation, Carl Zeiss Meditec AG, a leading figure in the medical technology sector, has once again proven its resilience and capacity for growth amidst ongoing global challenges. The first half of the fiscal year 2021/22 has seen the company achieve a notable revenue increase to €855.4 million, up from €767.4 million in the previous year, marking an 11.5% growth (10.7% when adjusted for currency effects). This achievement is particularly commendable given the backdrop of a strained supply chain due to the war in Ukraine and COVID-19 lockdowns in China, as CEO Dr. Markus Weber highlighted.


Key Contributors to Growth

The presentation, led by the CEO and CFO, delves into the specifics of this growth, attributing it to significant contributions from all strategic business units and regions. Noteworthy is the Ophthalmic Devices segment, which saw a 10.5% revenue increase, and the Microsurgery segment, which experienced a 14.8% growth. With China and India leading the charge, the APAC region posted a 17.1% revenue increase, underscoring the company’s strong market presence in these countries.


Financial Highlights and Future Outlook

Despite the positive revenue growth and a slight increase in EBIT to €177.3 million, the company noted a slight dip in the EBIT margin to 20.7%, mainly due to planned higher investments in Sales & Marketing and R&D. Nevertheless, earnings per share rose to €1.44 from the previous year’s €1.12. Amidst these achievements, the company remains cautiously optimistic about the future, citing ongoing global supply chain strains and political uncertainties as potential hurdles. However, Carl Zeiss Meditec AG stands firm in its forecast for the fiscal year, anticipating revenue growth to match or surpass market trends, with an expected EBIT margin ranging between 19-21%.


This comprehensive overview showcases Carl Zeiss Meditec AG’s robust half-year performance and highlights its strategic approach to overcoming global market challenges. It offers valuable insights to professional stock investors regarding the company’s resilience and growth prospects.

Resources
Presentation
Carl Zeiss Meditec Video Hub
Podcast
Host
weber - Carl Zeiss Meditec AG Financial Results H1 2021/22 | Performance Insights with CEO and CFO -%sitename%

Dr. Markus Weber
CEO | Carl Zeiss Meditec AG

cfo - Carl Zeiss Meditec AG Financial Results H1 2021/22 | Performance Insights with CEO and CFO -%sitename%

Justus Felix Wehmer
CFO | Carl Zeiss Meditec AG

Linkedin
sebastian 1 - Carl Zeiss Meditec AG Financial Results H1 2021/22 | Performance Insights with CEO and CFO -%sitename%

Sebastian Frericks
Head IR | Carl Zeiss Meditec AG

Linkedin Envelope
Share
T&C:

This publication is for informational purposes only and should not be considered investment advice. By using this website, you agree to the terms and conditions outlined in the legal pages at www.seat11a.com/legal/

Discover Additional Elevator Pitches

Release Date

May 16, 2022

Duration

04:26

Director

Reviews for Carl Zeiss Meditec AG Financial Results H1 2021/22 | Performance Insights with CEO and CFO
There are currently no reviews for Carl Zeiss Meditec AG Financial Results H1 2021/22 | Performance Insights with CEO and CFO
COMPANIES:

Germany:

Austria:

Estonia:

Finland:

France:

Italy:

Poland:

Spain:

PRESENTATIONS:
INDUSTRIES:
Linkedin Twitter Instagram Podcast Envelope Whatsapp

(c) seat11a – Publicly Listed Companies: Elevator Pitch, Deep-Dive, Financial Results, and ESG 

Unlock the insights of top publicly listed companies with seat11a.com

Elevate your understanding with powerful Elevator Pitches, Deep-Dive Presentations, and in-depth Financial Analysis

Scroll to top